Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Launched by ACE CELLS LAB LIMITED · Jan 16, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new treatment for certain eye diseases, specifically age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal dystrophies like retinitis pigmentosa (RP). The treatment uses a special type of medicine made from proteins and growth factors derived from fetal tissues and stem cells. Participants will take this treatment as a liquid under their tongue four times a day for one year. The main goal is to see if the treatment is safe and how well it works to improve vision and eye health.
To be eligible for the study, participants must be adults aged 18 to 65 with a diagnosis of RP and some level of vision in at least one eye. They should not have serious eye problems or recent eye surgery that could affect the study. Those who join will have regular check-ups to monitor their health and vision, including tests to measure their eyesight and imaging of their retinas. This study aims to find a new, less invasive way to help people with these challenging eye conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP.
- • Visual acuity of ≥1/60 in at least one eye.
- • Stable ocular and systemic condition over the past six months.
- • Ability to provide written informed consent
- Exclusion Criteria:
- • • Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy).
- • Recent ocular surgery (within six months) or current use of investigational drugs.
- • Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, autoimmune diseases).
- • Pregnancy or lactation.
About Ace Cells Lab Limited
Ace Cells Lab Limited is a forward-thinking clinical trial sponsor dedicated to advancing medical research and innovation in cell therapy and regenerative medicine. With a commitment to excellence, the company specializes in designing and conducting rigorous clinical trials that evaluate the safety and efficacy of cutting-edge treatments. Leveraging a team of experienced researchers and a robust infrastructure, Ace Cells Lab Limited collaborates with healthcare professionals and institutions to facilitate the development of novel therapies aimed at improving patient outcomes. Their mission is to bring transformative solutions to market while adhering to the highest standards of regulatory compliance and ethical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Giza, , Egypt
Patients applied
Trial Officials
Dr. Passant Sayed Saif, PhD ophthalmology
Principal Investigator
Associate prof of Ophthalmology Misr University for science and technology
Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology
Principal Investigator
Dean of NILES Prof of Ophthalmology Beni-Suef University
Dr. Alaa Abdelkarim Mohammed, MRCPUK Endocirnology
Principal Investigator
ACE Cells Lab Limited Chief Medical Consultant
Dr. Ahmed Tamer Sayed Saif, PhD Ophthalmology
Principal Investigator
Chairman of Ophthalmology department Associate prof of Ophthalmology Fayoum university
DR. Mike Chan, stem cells expert
Study Chair
European Wellness Academy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported